A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

被引:16
作者
Loebel, Antony [1 ]
Koblan, Kenneth S. [1 ]
Tsai, Joyce [1 ]
Deng, Ling [1 ]
Fava, Maurizio [2 ,3 ]
Kent, Justine [1 ]
Hopkins, Seth C. [1 ]
机构
[1] Sunovion Pharmaceut Inc, Marlborough, MA 01752 USA
[2] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
关键词
Bipolar disorder; Depressive disorder; Serotonin; 7; receptor; Enantiomer; Agents; Antidepressive; Amisulpride; EYE-MOVEMENT SLEEP; RECEPTOR ANTAGONIST SB-269970; RATING-SCALE; ANTIPSYCHOTIC-DRUGS; COMORBID ANXIETY; LURASIDONE; MONOTHERAPY; QUETIAPINE; OCCUPANCY; DISORDER;
D O I
10.1016/j.jad.2021.09.109
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Non-racemic amisulpride (SEP-4199) is an 85:15 ratio of aramisulpride:esamisulpride with a 5-HT7 and D2 receptor binding profile optimized for the treatment of bipolar depression. The aim of this study was to evaluate the efficacy and safety of SEP-4199 for the treatment of bipolar depression. Methods: Patients meeting DSM-5 criteria for bipolar I depression were randomized to 6 weeks of double-blind, placebo-controlled treatment with SEP-4199 200 mg/d or 400 mg/d. The primary endpoint was change in the Montgomery-Asberg Depression Rating Scale (MADRS) at Week 6. The primary efficacy analysis population consisted of patients in Europe and US (n = 289); the secondary efficacy analysis population (ITT; n = 337) included patients in Japan. Results: Endpoint improvement in MADRS total score was observed on both the primary analysis for SEP-4199200 mg/d (P = 0.054; effect size [ES], 0.31) and 400 mg/d (P = 0.054; ES, 0.29), and on the secondary (full ITT)analysis for SEP-4199 200 mg/d (P = 0.016; ES, 0.34) and 400 mg/d (P = 0.024; ES, 0.31). Study completionrates were 81% on SEP-4199 200 mg/d, 88% on 400 mg/d, and 86% on placebo. SEP-4199 had low rates ofindividual adverse events (<8%) and minimal effects on weight and lipids; median increases in prolactin were+83.6 mu g/L on 200 mg/d, +95.2 mu g/L on 400 mg/d compared with 0.0 mu g/L on placebo. Limitations: The study excluded patients with bipolar II depression and serious psychiatric or medical comorbidity. Conclusion: Study results provide preliminary proof of concept, needing confirmation in subsequent randomized trials, for the efficacy of non-racemic amisulpride in bipolar depression.
引用
收藏
页码:549 / 558
页数:10
相关论文
共 62 条
  • [1] Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
    Abbas, Atheir I.
    Hedlund, Peter B.
    Huang, Xi-Ping
    Tran, Thuy B.
    Meltzer, Herbert Y.
    Roth, Bryan L.
    [J]. PSYCHOPHARMACOLOGY, 2009, 205 (01) : 119 - 128
  • [2] American Psychiatric Association, 2022, Diagnostic and statistical manual of mental disorders, V5th ed., text rev., DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
  • [3] The Barnes Akathisia Rating Scale - Revisited
    Barnes, TRE
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (04) : 365 - 370
  • [4] Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III
    Blanco, Carlos
    Compton, Wilson M.
    Saha, Tulshi D.
    Goldstein, Benjamin I.
    Ruan, W. June
    Huang, Boji
    Grant, Bridget F.
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2017, 84 : 310 - 317
  • [5] Translational Evaluation of JNJ-18038683, a 5-Hydroxytryptamine Type 7 Receptor Antagonist, on Rapid Eye Movement Sleep and in Major Depressive Disorder
    Bonaventure, Pascal
    Dugovic, Christine
    Kramer, Michelle
    De Boer, Peter
    Singh, Jaskaran
    Wilson, Sue
    Bertelsen, Kirk
    Di, Jianing
    Shelton, Jonathan
    Aluisio, Leah
    Dvorak, Lisa
    Fraser, Ian
    Lord, Brian
    Nepomuceno, Diane
    Ahnaou, Abdellah
    Drinkenburg, Wilhelmus
    Chai, Wenying
    Dvorak, Curt
    Sands, Steve
    Carruthers, Nicholas
    Lovenberg, Timothy W.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 342 (02) : 429 - 440
  • [6] Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients
    Bressan, RA
    Erlandsson, K
    Spencer, EP
    Ell, PJ
    Pilowsky, LS
    [J]. PSYCHOPHARMACOLOGY, 2004, 175 (03) : 367 - 373
  • [7] Validation of Electronic Health Record Phenotyping of Bipolar Disorder Cases and Controls
    Castro, Victor M.
    Minnier, Jessica
    Murphy, Shawn N.
    Kohane, Isaac
    Churchill, Susanne E.
    Gainer, Vivian
    Cai, Tianxi
    Hoffnagle, Alison G.
    Dai, Yael
    Block, Stefanie
    Weill, Sydney R.
    Nadal-Vicens, Mireya
    Pollastri, Alisha R.
    Rosenquist, J. Niels
    Goryachev, Sergey
    Ongur, Dost
    Sklar, Pamela
    Perlis, Roy H.
    Smoller, Jordan W.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2015, 172 (04) : 363 - 372
  • [8] Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype
    Cates, Lindsay N.
    Roberts, Amanda J.
    Huitron-Resendiz, Salvador
    Hedlund, Peter B.
    [J]. NEUROPHARMACOLOGY, 2013, 70 : 211 - 217
  • [9] Initial Validity and Reliability Data on the Columbia-Suicide Severity Rating Scale
    Chappell, Phillip
    Feltner, Douglas E.
    Makumi, Clare
    Stewart, Michelle
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2012, 169 (06) : 662 - 663
  • [10] Genetic validation of bipolar disorder identified by automated phenotyping using electronic health records
    Chen, Chia-Yen
    Lee, Phil H.
    Castro, Victor M.
    Minnier, Jessica
    Charney, Alexander W.
    Stahl, Eli A.
    Ruderfer, Douglas M.
    Murphy, Shawn N.
    Gainer, Vivian
    Cai, Tianxi
    Jones, Ian
    Pato, Carlos N.
    Pato, Michele T.
    Landen, Mikael
    Sklar, Pamela
    Perlis, Roy H.
    Smoller, Jordan W.
    [J]. TRANSLATIONAL PSYCHIATRY, 2018, 8